Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers

Breast Cancer Research

Volumn 12, Issue 2, 2010, Pages

  Song, Chang H ^a   Park, So Y ^b   Eom, Keun Yong ^a   Kim, Jee H ^a   Kim, Sung Won ^a   Kim, Jae S ^a   Kim, In A ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P42; PROTEIN P44; PROTEIN S6; RAF PROTEIN; S6 KINASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RELAPSE; CANCER STAGING; CELL PROLIFERATION; DISEASE MARKER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; FEMALE; KAPLAN MEIER METHOD; METABOLISM; PREDICTION AND FORECASTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; BREAST NEOPLASMS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954080953     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2557     Document Type: Article

References (36)

1. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer 1991, 68:2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D, 1913453.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
3. Clark GM, McGuire WL, Hubay CA, Pearson OH, Carter A. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res 1983, 132E:183-190.
4. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992, 10:1284-1291.
5. Grann VR, Troxel AB, Zojwalla NJ, Grann VR, Troxel AB, Zojwalla NJ. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005, 103:2241-2251. 10.1002/cncr.21030, 15844176.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
7. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8:103-112.
8. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, . the International Breast Cancer Study Group Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors: a surrogate marker?. Cancer 2003, 97:1321-1331. 10.1002/cncr.11188, 12599241, the International Breast Cancer Study Group.
9. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306:1506-1507. 10.1126/science.1105396, 15567848.
10. Huang MC, Lau YK. Basic science of HER2/neu: a review. Semin Oncol 1999, 26:51-59.
11. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
12. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003, 15:419-424. 10.1097/00001622-200311000-00003, 14624223.
13. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kücücük S, Dincer M, Aydiner A, Topuz E. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 2008, 19:669-674. 10.1093/annonc/mdm522, 18006896.
14. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 2008, 15:1064-1069. 10.1245/s10434-007-9751-7, 18183466.
15. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104:7564-7569. 10.1073/pnas.0702507104, 1855070,1855070, 17452630.
16. Schmitz KJ, Otterbach F, Callies R, Levkau B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 2004, 17:15-21. 10.1038/modpathol.3800002, 14631376.
17. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002, 86:540-545. 10.1038/sj.bjc.6600126, 2375266, 11870534.
18. Hage JA, Broek LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, Velde CJ, Vijver MJ. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 2004, 90:1543-1550. 10.1038/sj.bjc.6601741, 2409704, 15083183.
19. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245. 10.1038/modpathol.3800525, 16341149.
20. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937. 10.1158/0008-5472.CAN-06-4511, 17409397.
21. Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008, 61:317-321. 10.1136/jcp.2007.050336, 17761736.
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
23. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
24. Engelman JA, Luo J, Catley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619. 10.1038/nrg1879, 16847462.
25. Lee JY, Engelman JA, Catley LC. PI3K charges ahead. Science 2007, 317:206-207. 10.1126/science.1146073, 17626872.
26. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of PI3KA gene in ovarian an d breast cancers. Clin Can Res 2005, 11:2875-2878.
27. Cully M, You H, Levine AJ, Mak TW, Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184-192. 10.1038/nrc1819, 16453012.
28. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
29. Kim IA, Bae SS, Fernandes AM, Wu JM, Muschel RJ, McKenna GW, Birnbaum MJ, Bernhard EJ. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005, 65:7902-7910.
30. No M, Choi EJ, Kim IA. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 2009, 8:2351-2361. 10.1158/1535-7163.MCT-08-0801, 19923913.
31. Powers M, Workman P. Targeting multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13:S125-S135. 10.1677/erc.1.01324, 17259553.
32. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of HSP90 confers tumour selectivity on HSP90 inhibitors. Nature 2003, 425:407-410. 10.1038/nature01913, 14508491.
33. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of HSP90 function by ansamycin sensitize breast cancer cells to chemotherapy-induced apoptosis in a RB- and schedule-dependent manner. Clin Cancer Res 2001, 7:2228-2236.
34. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
35. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
36. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10:R101. 10.1186/bcr2204, 2656897, 19055754.